Natco Pharma Stock Jumps 2.5% Following Launch of Generic Semaglutide Multi-Dose Vials in India
Loading more articles...
Natco Pharma Shares Surge 2.5% on Launch of Generic Semaglutide Injection
M
Moneycontrol•20-03-2026, 11:23
Natco Pharma Shares Surge 2.5% on Launch of Generic Semaglutide Injection
•Natco Pharma shares rose 2.5% after launching generic Semaglutide Injection (multi-dose vials) in India on patent expiry day.
•The company received CDSCO approval in February 2026 to manufacture and market generic Semaglutide.
•Semaglutide is used to treat adults with insufficiently controlled type 2 diabetes mellitus.
•Natco's generic Semaglutide will be available under brand names SEMANATTM and SEMAFULLTM, with multi-dose vials priced significantly lower than pen devices and innovator brands.
•Natco is the first to offer generic Semaglutide in vial dosage form, making GLP-1 therapy more accessible and affordable in India.
